Αρχική World News Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term Survivors...

Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term Survivors of AYA Cancer

In an article published on 16 July 2020 in the Journal of Clinical Oncology, the researchers of the Kaiser Permanente Southern California in Pasadena, CA, USA described the incidence and relative risk of development of chronic comorbidities among survivors of adolescent and young adult (AYA) cancer compared with controls without a history of cancer. They found that the risk of nearly all comorbidities was significantly elevated in survivors of cancer, with magnitudes of incidence rate ratio (IRR) ranging from 1.3 for dyslipidaemia to 8.3 for avascular necrosis. Moreover, 2 in 5 survivors had multiple comorbidities just 10 years after the index date. Among survivors of AYA cancer, the study team observed significant associations between treatment exposures and certain comorbidities such as cardiomyopathy, hearing loss, stroke, thyroid disorders, and diabetes. The data highlight the burden of adverse long-term health outcomes of cancer and its treatment in survivors of AYA cancer and will facilitate the identification of high-risk survivors who may benefit from tailored surveillance and prevention strategies.

To describe the incidence, relative risk, and risk factors for chronic comorbidities in survivors of AYA cancer, this retrospective cohort study included 2-year survivors of AYA cancer diagnosed between age 15 and 39 years at Kaiser Permanente Southern California from 2000 to 2012. A comparison cohort without cancer was individually matched (13:1) to survivors of cancer on age, sex, and calendar year.

By using electronic medical records, all participants were followed through 31 December 2014 for chronic comorbidity diagnoses. Poisson regression was used to evaluate the association between cancer survivor status and risk of developing each comorbidity. The associations between cumulative exposure to chemotherapy and radiation therapy and selected comorbidities were examined for AYA survivors of cancer.

The cohort included 6,778 survivors of AYA cancer and 87,737 persons without a history of cancer. Among survivors of AYA cancer, median age at initial cancer diagnosis was 31 years (8% of age 15-19 years; 25% of age 20-29 years; and 67% of age 30-39 years). Approximately 65% of survivors were female, and 42% were non-Hispanic White.

The most common cancer diagnoses were breast cancer (16%) and thyroid cancer (16%), followed by lymphoma (11%) and melanoma (10%). Approximately a quarter of survivors of AYA cancer (23%) received external-beam radiation therapy. Exposure to selected chemotherapy agents ranged from 3% in case of epipodophyllotoxins to 24% for anthracyclines. The median follow-up time after cancer diagnosis was 5.1 years.

The IRR for survivors of cancer was significantly increased for nearly all comorbidities examined. The IRR ranged from 1.3 (95% confidence interval [CI], 1.2 to 1.4) for dyslipidaemia to 8.3 (95% CI, 4.6 to 14.9) for avascular necrosis.

Survivors of AYA cancer had a 2- to 3-fold increased risk for cardiomyopathy, stroke, premature ovarian failure, chronic liver disease, and renal failure.

Among survivors of cancer, significant associations between chemotherapy and radiation therapy exposures and late effects of cardiomyopathy, hearing loss, stroke, thyroid disorders, and diabetes were observed from the multivariable analyses.

The authors reported that 40% of survivors of AYA cancer had multiple (≥2) comorbidities at 10 years after index date, compared with 20% of those without cancer.

The authors concluded that findings from their study provide a comprehensive overview of the incidence and relative risk of chronic comorbidities in long-term survivors of AYA cancer compared with matched individuals without a history of cancer. They showed that the risk of developing chronic comorbidities was increased across nearly all outcomes examined and highlighted important treatment-related modifiers of risk in survivors of AYA cancer. These data may help provide much-needed information for the development of personalised survivorship care plans for survivors of AYA cancer, taking into consideration the unique phenotypes of comorbidities over time. Furthermore, it may set the stage for prevention, early diagnosis, or intervention strategies to mitigate long-term comorbidity burden in this growing population of long-term survivors.

The study was supported by grant from the American Cancer Society.


Chao C, Bhatia S, Xu L, et al. Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer. JCO; Published online 16 July 2020. DOI10.1200/JCO.20.00722.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...